MediWound Ltd.

MediWound Ltd. develops and commercializes enzymatic therapeutics for tissue repair, primarily using bromelain extracted from pineapple stems. The company’s lead product, NexoBrid, is approved for the removal of dead tissue in severe burns and is derived from this plant-based source. While its current commercial products are not animal-derived, the company’s core business of biopharmaceutical development inherently involves animal testing as a required component of the regulatory pathway for drug approval. This places MediWound within the broad category of companies that rely on animal research to bring medical products to market.

Public SEC filings list compliance with the Animal Welfare Act and other federal statutes governing animal research as a standard regulatory risk. The available evidence does not specify the scale, species, or internal welfare standards of MediWound’s animal testing operations. Without a publicly available animal testing policy or commitment to alternative methods, the company’s operations fall under the general exclusion for commercial activities that exploit animals.